摘要
目的：比较血管紧张素Ⅱ受体拮抗药（ARB）在我院高血压合并高尿酸血症患者中应用的疗效及经济学差异。方法：回顾性分析2014年1-10月在我院确诊高血压合并高尿酸血症的住院患者283例,根据使用ARB品种分为厄贝沙坦组（68例）、缬沙坦组（72例）、替米沙坦组（70例）、氯沙坦钾组（73例）,比较4组治疗前后血压、血尿酸的变化情况,药品费用及不良反应发生率。结果：各组治疗后的收缩压和舒张压较治疗前明显下降（P〈0.05）;各组治疗后的血尿酸水平与治疗前差异有统计学意义（P〈0.05）,氯沙坦钾组治疗后的血尿酸水平明显低于其他组（P〈0.01）。4组患者使用药物费用差异有统计学意义（P〈0.05）。结论：4种ARB类药物均能有效治疗高血压,氯沙坦钾除了有效控制血压外,降低血尿酸水平优于其他ARB类药物。
Objective： To compare efficacy of angiotensin Ⅱ receptor blockers（ ARB） for patients with hypertension companied by hyperuricemia. Methods： Using retrospectively analysis,283 cases of patients with hypertension companied by hyperuricemia in our hospital from January to October of 2014 were assigned to irbesartan group（ n = 68）,valsartan group（ n = 72）,telmisartan group（ n = 70） and losartan potassium group（ n = 73） according to the ARB kinds. The blood pressure,uric acid and incidence of adverse drug reactions of each group were compared. Results： There were significantly decreased of systolic and diastolic blood pressure after treatment（ P〈0. 05）. The blood uric acid level had significant difference after treatment（ P〈0. 05）. Blood uric acid levels of losartan potassium group was obviously lower than others after treatment（ P〈0. 01）. There were significant differences in drug costs between the four groups（ P〈0. 05）. Conclusion： The four kinds of ARB could effectively cure high blood pressure,except effective control of blood pressure,losartan potassium could better lower blood uric acid level than other ARB.
出处
《药物流行病学杂志》
CAS
2016年第3期185-187,共3页
Chinese Journal of Pharmacoepidemiology
